Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) SEC filings page on Stock Titan provides structured access to the company’s U.S. regulatory disclosures. As a British Columbia–incorporated, globally active pharmaceutical issuer with common shares listed on the New York Stock Exchange and Toronto Stock Exchange, Bausch Health files a variety of documents with the U.S. Securities and Exchange Commission under Commission File Number 001-14956.
Investors can review current reports on Form 8-K that describe material events such as exchange offers for senior secured notes, amendments to credit agreements at Bausch Health and Bausch + Lomb, completion of acquisitions like DURECT Corporation, quarterly financial results, shareholder meeting outcomes and other significant corporate actions. These filings also summarize key terms of new 10.00% Senior Secured Notes due 2032, related indentures and collateral arrangements, including pledges of Bausch + Lomb shares.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically provide more comprehensive detail on Bausch Health’s segments—Salix, International, Solta Medical, Diversified Products and Bausch + Lomb—along with risk factors, management’s discussion and analysis and notes on non-GAAP metrics the company uses, such as organic revenue growth and adjusted EBITDA. Proxy materials and governance-related filings give additional insight into matters like the Amended and Restated Shareholder Rights Plan Agreement and shareholder voting results.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users understand changes in debt structure, covenant terms, segment performance and strategic transactions without reading every page. Real-time updates from EDGAR, along with visibility into items such as potential insider transaction reports on Form 4, allow users to monitor how Bausch Health reports its financial condition, capital structure decisions and corporate governance developments over time.
Bausch Health Companies Inc. filed a current report to let investors know it has released its financial results for the quarter ended September 30, 2025. On October 29, 2025, the company issued a press release covering its results of operations and other financial information for that quarter, which is included as Exhibit 99.1.
The company states that this information is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and will not be incorporated by reference into securities offering documents. The filing is mainly a formal notice pointing readers to the detailed third-quarter 2025 results contained in the attached press release.
Bausch Health Companies Inc. reported the results of a Special Meeting of Shareholders held on October 7, 2025. Shareholders voted on an ordinary resolution to ratify, confirm and approve the adoption of the company’s Amended and Restated Shareholder Rights Plan Agreement dated April 14, 2025 and amended and restated on August 25, 2025. The resolution was approved, with 178,244,775 votes cast for and 40,130,633 votes cast against. The Rights Plan Agreement is described in detail in the company’s Management Proxy Circular and Proxy Statement dated August 27, 2025.
Amendment corrects previously reported insider holdings. This Form 4/A updates an earlier filing to state that John Paulson indirectly beneficially owned 70,755,869 common shares of Bausch Health Companies Inc. as of the 09/30/2025 transaction date. The amendment says the corrected amount matches what was reported on a prior Form 4 filed 08/14/2025 and attributes the holdings to funds managed by Paulson Capital Inc., while the reporting person disclaims direct beneficial ownership except for any pecuniary interest. The filing was signed by an attorney-in-fact on 10/06/2025.
John Paulson, a director of Bausch Health Companies Inc. (BHC), received 9,689 restricted share units on 09/30/2025 as compensation for board service for the quarter ended that date; each unit vests into one common share. After the grant, Mr. Paulson directly beneficially owns 351,128 common shares. In addition, he may be deemed an indirect beneficial owner of 32,791,702 common shares held by investment funds managed by Paulson Capital Inc., although the filing disclaims beneficial ownership except to the extent of any pecuniary interest. The transaction was reported on Form 4 and signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies director Sandra Leung was granted 3,673 restricted share units (RSUs) issued in lieu of cash compensation for her service on the board for the quarter ending September 30, 2025. Each RSU represents a contingent right to receive one common share. After the award, the reporting person beneficially owned 33,822 common shares. The transaction was reported on a Form 4 and executed under transaction code V, with the RSUs recorded at $0 price as issued units rather than an open-market purchase.
Bausch Health Companies Inc. director Amy B. Wechsler received 1,065 restricted share units on 09/30/2025 issued in lieu of cash compensation for board service. Each restricted share unit represents a contingent right to one common share and was reported as having a $0 cash price. After the grant, the reporting person beneficially owned 265,452 common shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies Inc. disclosed a contractual mechanism tied to the company’s transaction with DURECT Corporation that grants each share a non-transferable contingent value right (CVR). The CVR represents the holder’s pro rata claim on two milestone payments that together can total up to
Seana Carson, EVP and General Counsel of Bausch Health Companies Inc. (BHC), reported two transactions in a Form 4. On 09/05/2025 the filing shows 51,337 shares were withheld to satisfy tax withholding obligations upon vesting of restricted share units at an indicated price of $7.35, leaving 512,955 shares beneficially owned. On 09/08/2025 the filing shows 13,370 shares sold in the open market pursuant to a Rule 10b5-1 plan at $7.31, reducing beneficial ownership to 499,585 shares.
The Form 4 is signed by an attorney-in-fact on behalf of the reporting person on 09/08/2025. Notes in the filing explicitly state the withholding was for tax obligations on RSU vesting and the sale was executed under a 10b5-1 plan adopted May 7, 2025.
Bausch Health Companies Inc (BHC) filed a Form 144 reporting a proposed sale of 13,370 common shares held at Fidelity Brokerage Services. The filing lists an aggregate market value of $97,734.70 and shows approximately 369,790,319 shares outstanding. The proposed sale is scheduled around 09/08/2025. The shares were acquired on 09/05/2025 through restricted stock vesting and were paid as compensation on the same date. The filer reports no other sales in the past three months and attests to the absence of undisclosed material adverse information.
Bausch Health Companies Inc. (BHC) is soliciting shareholder votes for a Special Meeting to ratify an Amended and Restated Shareholder Rights Plan (the "Rights Agreement"). Shareholders of record as of August 18, 2025 may vote at a virtual Special Meeting scheduled for October 7, 2025. The proxy materials were first mailed on or about August 27, 2025 and are available on the company website and regulatory filers.
The Rights Agreement creates transferable rights attached to each common share that, upon certain triggering events (the "Separation Time" following an "Acquiring Person" obtaining 20% of voting shares or other specified takeover events), become exercisable to purchase common shares at an Exercise Price equal to three times the Market Price (Market Price defined as the 20-day average closing price). The plan contains customary anti-dilution adjustments, a redemption price of $0.00001 per Right, carve-outs for Permitted/Competing Permitted Bids, a requirement to reconfirm the plan every third annual meeting, and other procedural and governance provisions. The filing states 369,800,365 common shares were outstanding as of August 18, 2025 and quorum requires holders of at least 25% of outstanding voting shares.